Champions Financial Statements From 2010 to 2024

CSBR Stock  USD 4.55  0.28  6.56%   
Champions Oncology financial statements provide useful quarterly and yearly information to potential Champions Oncology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Champions Oncology financial statements helps investors assess Champions Oncology's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Champions Oncology's valuation are summarized below:
Gross Profit
24.3 M
Profit Margin
(0.07)
Market Capitalization
58 M
Enterprise Value Revenue
1.2185
Revenue
51.7 M
There are over one hundred nineteen available fundamental signals for Champions Oncology, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to validate Champions Oncology's prevailing fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction. As of 11/22/2024, Market Cap is likely to drop to about 46 M. In addition to that, Enterprise Value is likely to drop to about 44.4 M

Champions Oncology Total Revenue

52.66 Million

Check Champions Oncology financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Champions Oncology's main balance sheet or income statement drivers, such as Depreciation And Amortization of 2 M, Interest Expense of 38.3 K or Selling General Administrative of 11.6 M, as well as many indicators such as Price To Sales Ratio of 1.24, Dividend Yield of 0.0033 or Days Sales Outstanding of 72.79. Champions financial statements analysis is a perfect complement when working with Champions Oncology Valuation or Volatility modules.
  
Check out the analysis of Champions Oncology Correlation against competitors.
To learn how to invest in Champions Stock, please use our How to Invest in Champions Oncology guide.

Champions Oncology Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets27.4 M26.1 M16.3 M
Slightly volatile
Short and Long Term Debt Total7.8 M7.4 M3.1 M
Slightly volatile
Other Current Liabilities739.7 K973 K948.1 K
Slightly volatile
Total Current Liabilities22.6 M21.5 M9.9 M
Slightly volatile
Property Plant And Equipment Net12.6 M12 M5.6 M
Slightly volatile
Accounts Payable6.1 M5.8 M2.6 M
Slightly volatile
Cash3.7 M2.6 M5.2 M
Pretty Stable
Non Current Assets Total13.1 M12.5 M6.3 M
Slightly volatile
Non Currrent Assets Other194.2 K185 K135.6 K
Pretty Stable
Cash And Short Term Investments3.7 M2.6 M5.2 M
Pretty Stable
Net Receivables10 M9.5 M4.3 M
Slightly volatile
Common Stock Total Equity24.7 K16.1 K26.9 K
Slightly volatile
Common Stock Shares Outstanding14.2 M13.5 M9.9 M
Slightly volatile
Liabilities And Stockholders Equity27.4 M26.1 M16.3 M
Slightly volatile
Non Current Liabilities Total6.8 M6.5 M3.8 M
Slightly volatile
Other Current Assets1.6 M1.5 M711.5 K
Slightly volatile
Other Stockholder Equity86.8 M82.7 M62.6 M
Slightly volatile
Total Liabilities29.4 M28 M13.7 M
Slightly volatile
Property Plant And Equipment Gross23.5 M22.4 M7.1 M
Slightly volatile
Total Current Assets14.3 M13.6 M10.1 M
Slightly volatile
Common Stock24.7 K16.1 K26.9 K
Slightly volatile
Other Liabilities500.9 K633.6 K550.6 K
Pretty Stable
Other Assets16.4 K17.2 K99.8 K
Slightly volatile
Short Term Debt2.8 M2.7 M791.7 K
Slightly volatile
Property Plant Equipment17.5 M16.7 M6.3 M
Slightly volatile
Current Deferred Revenue12.7 M12.1 M5.6 M
Slightly volatile
Intangible Assets650.6 K769.4 K641.9 K
Slightly volatile
Good Will456.3 K301.5 K540.8 K
Slightly volatile
Capital Surpluse77.6 M94.3 M67.1 M
Slightly volatile
Non Current Liabilities Other380.9 K401 K1.4 M
Slightly volatile
Short and Long Term Debt42 K37.8 K51.5 K
Slightly volatile
Long Term Debt Total12.8 K14.4 K15.7 K
Slightly volatile
Capital Lease Obligations7.1 M7.4 M3.1 M
Slightly volatile
Capital Stock14.7 K16.1 K12.9 K
Slightly volatile

Champions Oncology Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And AmortizationM1.9 M951.7 K
Slightly volatile
Selling General Administrative11.6 M11.1 M6.4 M
Slightly volatile
Total Revenue52.7 M50.2 M26.1 M
Slightly volatile
Gross Profit21.8 M20.8 M11.4 M
Slightly volatile
Other Operating Expenses60.4 M57.5 M30.9 M
Slightly volatile
Cost Of Revenue30.9 M29.4 M14.7 M
Slightly volatile
Total Operating Expenses29.5 M28.1 M16.3 M
Slightly volatile
Selling And Marketing Expenses4.3 M7.1 M4.1 M
Slightly volatile
Research Development5.2 M9.5 M5.2 M
Slightly volatile
Interest Income316 K355.5 K387.1 K
Slightly volatile
Reconciled Depreciation1.2 M1.9 M740.8 K
Slightly volatile
Non Recurring268 K301.5 K328.3 K
Slightly volatile

Champions Oncology Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow10.6 M10.1 M6.2 M
Slightly volatile
DepreciationM1.9 M787 K
Slightly volatile
End Period Cash Flow3.7 M2.6 M5.2 M
Pretty Stable
Stock Based Compensation1.3 M1.1 M1.6 M
Slightly volatile
Change To Netincome1.6 M1.7 M2.3 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.241.31012.9564
Slightly volatile
Dividend Yield0.00330.00370.0041
Slightly volatile
Days Sales Outstanding72.7969.324949.9268
Slightly volatile
Average Payables61.6 K47.7 K43.4 K
Slightly volatile
Stock Based Compensation To Revenue0.02120.02230.1381
Slightly volatile
Capex To Depreciation0.430.44781.8384
Pretty Stable
EV To Sales1.341.4062.6986
Slightly volatile
Inventory Turnover33.8834.5129.9781
Slightly volatile
Days Of Inventory On Hand0.00.01.1478
Slightly volatile
Payables Turnover4.825.06916.7003
Pretty Stable
Sales General And Administrative To Revenue0.420.22070.3636
Slightly volatile
Average Inventory0.550.571.5 K
Slightly volatile
Research And Ddevelopement To Revenue0.320.19030.2566
Pretty Stable
Capex To Revenue0.02220.01670.0385
Pretty Stable
Cash Per Share0.180.19320.7105
Slightly volatile
Days Payables Outstanding57.6472.004465.6749
Pretty Stable
Intangibles To Total Assets0.01220.01280.1119
Slightly volatile
Current Ratio0.60.63321.3103
Slightly volatile
Receivables Turnover5.05.26518.4229
Slightly volatile
Graham Number1.731.30292.6383
Slightly volatile
Capex Per Share0.05530.06170.0975
Slightly volatile
Average Receivables12.4 K13.1 K14.6 K
Slightly volatile
Revenue Per Share2.723.70212.521
Slightly volatile
Interest Debt Per Share0.10.09870.0384
Slightly volatile
Debt To Assets0.03730.05120.031
Slightly volatile
Operating Cycle72.7969.324951.0746
Slightly volatile
Days Of Payables Outstanding57.6472.004465.6749
Pretty Stable
Ebt Per Ebit1.680.99351.3663
Slightly volatile
Quick Ratio0.60.63321.2975
Slightly volatile
Net Income Per E B T1.410.99561.2054
Slightly volatile
Cash Ratio0.120.12150.8599
Slightly volatile
Days Of Inventory Outstanding0.00.01.1478
Slightly volatile
Days Of Sales Outstanding72.7969.324949.9268
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.281.13621.0991
Very volatile
Fixed Asset Turnover3.984.18910.4734
Slightly volatile
Debt Ratio0.03730.05120.031
Slightly volatile
Price Sales Ratio1.241.31012.9564
Slightly volatile
Asset Turnover2.221.91931.7047
Pretty Stable
Gross Profit Margin0.530.41380.4122
Slightly volatile

Champions Oncology Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap46 M65.7 M63.2 M
Slightly volatile
Enterprise Value44.4 M70.5 M61 M
Slightly volatile

Champions Fundamental Market Drivers

Forward Price Earnings22.8833
Cash And Short Term Investments2.6 M

Champions Upcoming Events

20th of March 2024
Upcoming Quarterly Report
View
22nd of July 2024
Next Financial Report
View
31st of January 2024
Next Fiscal Quarter End
View
22nd of July 2024
Next Fiscal Year End
View
31st of October 2023
Last Quarter Report
View
30th of April 2023
Last Financial Announcement
View

About Champions Oncology Financial Statements

Champions Oncology shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Champions Oncology investors may analyze each financial statement separately, they are all interrelated. The changes in Champions Oncology's assets and liabilities, for example, are also reflected in the revenues and expenses on on Champions Oncology's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue12.1 M12.7 M
Total Revenue50.2 M52.7 M
Cost Of Revenue29.4 M30.9 M
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.22  0.42 
Research And Ddevelopement To Revenue 0.19  0.32 
Capex To Revenue 0.02  0.02 
Revenue Per Share 3.70  2.72 
Ebit Per Revenue(0.15)(0.15)

Pair Trading with Champions Oncology

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Champions Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Champions Oncology will appreciate offsetting losses from the drop in the long position's value.

Moving against Champions Stock

  0.4KTTAW Pasithea TherapeuticsPairCorr
The ability to find closely correlated positions to Champions Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Champions Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Champions Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Champions Oncology to buy it.
The correlation of Champions Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Champions Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Champions Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Champions Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Champions Stock Analysis

When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.